Nivolumab and immune-mediated colitis

Heather Walker; Paul Brennan; Maximillian Groome; Shaun Walsh; Frank Carey

doi:10.1002/ccr3.2027

Nivolumab and immune-mediated colitis

Heather Walker (Lead / Corresponding author), Paul Brennan, Maximillian Groome, Shaun Walsh, Frank Carey

Population Health and Genomics

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

155 Downloads (Pure)

Abstract

Nivolumab is associated with a number of immune-regulated adverse events, including immune-mediated colitis and may present following the discontinuation of treatment. Current guidance suggests lower doses of methylprednisolone; however, we described faster resolution of the patient's symptoms compared to previous reported cases, using higher dosing, thereby minimizing hospitalization.

Original language	English
Pages (from-to)	644-647
Number of pages	4
Journal	Clinical Case Reports
Volume	7
Issue number	4
Early online date	19 Feb 2019
DOIs	https://doi.org/10.1002/ccr3.2027
Publication status	Published - 8 Apr 2019

Keywords

immune-mediated colitis
immune-regulated adverse events
Nivolumab
PD-1 receptor

ASJC Scopus subject areas

General Medicine

Access to Document

10.1002/ccr3.2027Licence: CC BY

Final Published VersionFinal published version, 253 KBLicence: CC BY

Cite this

@article{a4ce9fe98af5455aa5da186af464172a,

title = "Nivolumab and immune-mediated colitis",

abstract = "Nivolumab is associated with a number of immune-regulated adverse events, including immune-mediated colitis and may present following the discontinuation of treatment. Current guidance suggests lower doses of methylprednisolone; however, we described faster resolution of the patient's symptoms compared to previous reported cases, using higher dosing, thereby minimizing hospitalization.",

keywords = "immune-mediated colitis, immune-regulated adverse events, Nivolumab, PD-1 receptor",

author = "Heather Walker and Paul Brennan and Maximillian Groome and Shaun Walsh and Frank Carey",

year = "2019",

month = apr,

day = "8",

doi = "10.1002/ccr3.2027",

language = "English",

volume = "7",

pages = "644--647",

journal = "Clinical Case Reports",

publisher = "Wiley",

number = "4",

}

TY - JOUR

T1 - Nivolumab and immune-mediated colitis

AU - Walker, Heather

AU - Brennan, Paul

AU - Groome, Maximillian

AU - Walsh, Shaun

AU - Carey, Frank

PY - 2019/4/8

Y1 - 2019/4/8

N2 - Nivolumab is associated with a number of immune-regulated adverse events, including immune-mediated colitis and may present following the discontinuation of treatment. Current guidance suggests lower doses of methylprednisolone; however, we described faster resolution of the patient's symptoms compared to previous reported cases, using higher dosing, thereby minimizing hospitalization.

AB - Nivolumab is associated with a number of immune-regulated adverse events, including immune-mediated colitis and may present following the discontinuation of treatment. Current guidance suggests lower doses of methylprednisolone; however, we described faster resolution of the patient's symptoms compared to previous reported cases, using higher dosing, thereby minimizing hospitalization.

KW - immune-mediated colitis

KW - immune-regulated adverse events

KW - Nivolumab

KW - PD-1 receptor

UR - http://www.scopus.com/inward/record.url?scp=85064046599&partnerID=8YFLogxK

U2 - 10.1002/ccr3.2027

DO - 10.1002/ccr3.2027

M3 - Article

C2 - 30997054

AN - SCOPUS:85064046599

VL - 7

SP - 644

EP - 647

JO - Clinical Case Reports

JF - Clinical Case Reports

IS - 4

ER -

Nivolumab and immune-mediated colitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this